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Introduction
Current research on circulating tumor cells (CTCs) 
present in the peripheral blood and disseminated tumor 
cells (DTCs) present in bone marrow provides new 
insight into the biology of tumor dormancy and tumor 
cell dissemination and will open new avenues for the 
early detection of metastatic spread and its successful 
treatment [1]. Th  e 7th International Symposium on 
Minimal Residual Cancer, organized by Evi Lianidou, 
Dimitris Mavroudis, and Klaus Pantel, was held in 
Athens, Greece on 16 to 19 September 2009. Th  e  sympo-
sium brought together 220 basic and clinical researchers 
who presented cutting-edge research and had an excel-
lent opportunity to have stimulating intense discussions 
on new technologies and clinical implications of CTC/
DTC detection. We summarize in this report the major 
ﬁ  ndings presented by invited speakers of this meeting.
Biology of metastasis and tumor dormancy
Danny R Welch (University of Alabama, Birmingham, AL, 
USA) presented a vivid account of metastasis sup  pres  sors, 
and especially breast cancer metastasis suppres  sor 1 
(BRMS1), which is signiﬁ  cantly downregulated in meta-
static disease by epigenetic silencing [2] and co  ordinately 
regulates expression of multiple metastasis-associated 
micro  RNAs [3]. BRMS1 diﬀ  erentially attenu  ates cellular 
responses to mitogenic signals at varying steps within the 
same signaling cascade, and speciﬁ   c modu  lation of 
signaling responses received from the micro  environment 
may ultimately dictate which environ  ments are permissive 
or restrictive for tumor cell growth [3,4].
George Calin (MD Anderson Cancer Center, Houston, 
TX, USA) described the roles of microRNAs as meta-
stasis activators or suppressors. His concept that the 
same microRNAs could be involved in both the CSC 
phenotype and the ability of speciﬁ  c cancer cells to give 
rise to metastases represents a mechanistic link between 
the initial and the ﬁ  nal steps of tumorigenesis [5].
Jean-Paul Th   iery (IMCB A STAR, Biopolis, Singapore)
illustrated how epithelial-mesenchymal transition (EMT) 
can play a major role in local and distant dissemination of 
carcinomas. Understanding of the molecular mechanisms 
regulating EMT in solid tumors will provide new insights 
into mechanisms of cancer progression, detection of 
metastases, and development of eﬀ  ective and mechanism-
based agents for improved therapeutic intervention [6].
Philip Tsichlis (Tufts University, Boston, MA, USA) 
highlighted how microRNAs diﬀ  erentially regulated by 
Akt isoforms control EMT and stem cell renewal in 
cancer cells. His data show that induction of EMT, stem 
cell renewal, cell survival and proliferation is controlled 
by microRNAs whose abundance depends on the balance 
between Akt1 and Akt2 rather than on the overall activity 
of Akt [7].
In a stimulating lecture Julio Aguirre-Ghiso (Mount 
Sinai School of Medicine, New York, NY, USA) reported 
on the roles of stress signaling and the microenvironment 
as regulators of tumor cell dormancy. Interestingly, 
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the activation of tumor growth factor-beta signaling and 
p38 activation, p53 induction, and ERK inhibition in D-
HEp3 cells, indicating that microenvironment-derived 
signals that impinge on stress signaling pathways might 
be suﬃ   cient to induce a protracted state of cellular tumor 
dormancy [8].
Ann Chambers (University of Western Ontario, London, 
Ontario, Canada) presented a stimulating update on 
imag  ing of experimental cancer metastasis and tumor 
dormancy recapitulated in a three-dimensional cell cul-
ture system. Initiation of proliferation and mainte  nance 
of metastatic growth by a subset of cells delivered to 
secondary sites represent rate-limiting steps, but a larger 
population of cells that remain in a dormant state appears 
to be resistant to cytotoxic chemotherapy and retains 
metastasis-forming potential [9].
Lisa M Coussens (University of California, San Fran-
cisco, CA, USA) indicated that anti-tumor-acquired 
immunity mediated by CD4+ T lymphocytes may pro-
mote cancer by engaging cellular components of the 
innate immune system and identify TH2-polarized CD4+ 
T lymphocytes as potential targets for anti-cancer 
therapy [10].
Circulating tumor cells and cancer stem cells
Subsets of CTCs or DTCs have a putative breast cancer 
stem-cell phenotype. New data on tumor stem and/or 
progenitor cells and their involvement in metastasis were 
presented. Bone marrow appears to be a special reservoir 
for DTCs [11]. Michael F Clarke (Stanford Institute for 
Stem Cell Biology and Regenerative Medicine, CA, USA), 
one of the leaders in the ﬁ  eld of CSCs, gave a state of the 
art keynote lecture on the molecular analysis of normal 
and malignant epithelial stem cells. In his talk, Michael 
Clarke presented data on extensive molecular and cellular 
analyses of normal and malignant stem cells that have 
revealed new pathways that regulate self-renewal as well 
as resistance to cytotoxic therapies [12]. Maintenance of 
dormancy is critical for preservation of stem cell func-
tion; however, it is not clear if dormancy is in fact the 
interval (which may be long) between one cell division 
and the next, or represents a deﬁ  ned state in which stem 
cells actively enter and exit.
Andreas Trumpp (DKFZ, Heidelberg, Germany) referred 
to the identiﬁ  cation of a long-term dormant popu  lation 
within mouse hematopoietic stem cells (HSCs) that 
bears the Lin-Sca1+cKit+CD150+CD48-CD34- phenotype. 
Dormant HSCs were shown to harbor the vast majority 
of multi-lineage long-term self-renewal activity and to be 
eﬃ     ciently activated to self-renew in response to bone 
marrow injury or granulocyte colony-stimulating factor 
stimulation. After re-establishment of homeostasis, 
activated HSCs returned to dormancy, suggesting that 
HSCs reversibly switch from dormancy to self-renewal 
under conditions of hematopoietic stress. One of the 
reasons CSCs are thought to escape anti-proliferative 
chemo  therapy is their relative dormancy. Dr Trumpp 
showed that HSCs treated with interferon-alpha eﬃ   ci-
ently exit quiescence and are sensitized to chemotherapy 
drugs and that this eﬀ  ect is mediated by STAT1 or Sca-1. 
He also discussed the implications of these results for the 
design of strategies to target dormant chronic myeloid 
leukemia (CML) stem cells not targetable by imatinib 
alone [13].
Since CSCs survive standard cancer therapies and can 
theoretically regenerate the tumor even after killing the 
bulk of tumor cells, novel treatment strategies should 
eliminate CSCs in order to be eﬀ  ective. Signaling path-
ways that maintain CSCs represent attractive targets for 
these therapies. In his lecture, Hasan Korkaya (University 
of Michigan Comprehensive Cancer Center, Ann Arbor, 
MI, USA) reported that stem or progenitor cells in both 
normal breast tissue and breast tumors are dependent on 
the phosphatase and tensin homolog (PTEN)/phospho-
inositide 3-kinase (PI3K)/Akt pathway for their con-
tinued growth. He also showed that perifosine, an Akt 
inhibitor, could speciﬁ  cally target the tumorigenic breast 
CSCs growing in mice. He concluded that these ﬁ  ndings 
support the idea that selective targeting of breast CSCs 
through the PTEN/PI3K/Akt pathway may have impor-
tant clinical implications in the treatment of patients with 
breast cancer [14].
CTCs and DTCs as tumor biomarkers - clinical trials 
and therapeutics
CTC-based platforms were shown to be eﬀ  ective  for 
testing the eﬃ     cacy of novel drugs. Howard I Scher 
(Memorial Sloan-Kettering Cancer Center, New York, 
NY, USA) described the application of CTCs as a ‘liquid 
biopsy’ in the evaluation of two therapies directed at 
speciﬁ   c molecular alterations that contribute to the 
progres  sion of castration-resistant prostate cancer, the 
17,20-lyase inhibitor abiraterone, and MDV3100, a novel 
anti-androgen [15].
Bernard Polzer (University of Regensburg, Germany) 
has shown that detection of cytokeratin-positive (CK+) 
cells in bone marrow samples taken months to years after 
surgery had no impact on the survival of prostate cancer 
while the detection of epithelial cell adhesion molecule-
positive (EpCAM+) cells in the bone marrow after surgery 
was predictive of metastatic relapse. Using single cell 
comparative genomic hybridization this group has 
demonstrated that EpCAM+ cells harbored signiﬁ  cantly 
more genomic aberrations than CK+ cells, which may 
explain their high metastatic potential [16].
Th  e prognostic signiﬁ   cance of CTCs in early breast 
cancer was summarized by  Dimitris Mavroudis 
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adminis  tration of adjuvant chemotherapy, detection of 
CK19 mRNA-positive CTCs was associated with shorter 
disease-free survival (DFS) and overall survival (OS). 
Signiﬁ  cantly decreased DFS and OS were observed for the 
post-chemotherapy CTC-positive patients. Th  e  prognostic 
utility of monitoring CTCs during adjuvant tamoxifen 
therapy was also shown in patients with hormone 
receptor-positive tumors since failure of tamoxi  fen to 
eradicate CTCs was associated with shorter DFS and OS. 
Immunoﬂ  uorescent analysis of CTCs demonstrating the 
common expression of mole  cules such as phosphorylated 
focal adhesion kinase, phos  phory  lated PI3K, 
phosphorylated epidermal growth factor receptor, 
phosphorylated AKT, vascular endo  the  lial growth factor 
and its receptor, and hypoxia-inducible factor-1α in CTCs 
could be exploited for designing targeted therapies [17].
Human epidermal growth factor receptor 2 (HER2) 
status may be diﬀ   erent between primary tumor and 
minimal residual disease as reﬂ   ected by CTCs/DTCs 
accord    ing to Tanja Fehm (University of Tübingen, 
Germany). Th  is may be due to either the acquisition of 
HER2 ampliﬁ   cation during dissemination and tumor 
progression or due to a small subclone of HER2-positive 
cells in the primary tumor that has shed its tumor cells 
since the HER2-positive cells have a growth and survival 
advantage and can therefore be detected more frequently 
in bone marrow and blood. Th   ese results indicate that a 
substantial subset of HER2-negative breast cancer 
patients do not receive HER2-targeted therapy despite 
HER2-positive persistent tumor cells [18].
Bjorn Naume (Th   e Norwegian Radium Hospital, Oslo, 
Norway) presented data showing that DTC status is an 
independent predictor of systemic relapse and breast 
cancer death at both diagnosis and follow-up. Initial data 
from the SATT study, which includes more than 1,100 
breast cancer patients receiving non-taxane anthracycline-
containing adjuvant chemotherapy, indicate that the 
DTC status changed with secondary chemotherapy in a 
signiﬁ  cant proportion of patients.
Are DTCs or CTCs better for their predictive and 
prognostic value in breast cancer patients? Th  is  question 
was addressed by Jean Yves Pierga (Institute Curie, Paris, 
France). By summarizing data from eight published 
reports showing 66 to 94% concordance rates for DTC/
CTC detection, he concluded that DTC detection is of no 
clinical interest for metastatic breast cancer patients. 
However, for non-metastatic disease DTC detection 
constitutes an evidence-based level I prognostic factor 
and remains the reference method. On the contrary, Dr 
Pierga suggested that CTC detection has demonstrated 
prognostic and predictive value in metastatic breast 
cancer patients, while for early disease the level of 
evidence needs to be further substantiated.
Preliminary results of the SUCCESS trial were pre-
sented by  Wolfgang Janni (Heinrich-Heine-Universität, 
Düsseldorf, Germany). CTCs of 3,658 early breast cancer 
patients at primary diagnosis and during adjuvant 
chemotherapy as well as endocrine and bisphosphonate 
treatment were analyzed using the CellSearch System 
(Veridex; Warren, NJ, USA). While the presence of CTCs 
before systemic treatment did not show prognostic 
relevance for DFS and OS, persistence of CTCs after 
chemotherapy was a signiﬁ   cant predictor for both 
reduced DFS and OS. Dr Janni also pointed out that 
persisting CTCs after primary treatment may lead to an 
indication for extended adjuvant therapy, which needs to 
be investigated in future trials.
Massimo Cristofanilli (Fox Chase Cancer Center, 
Philadelphia, PA, USA) underscored that the prognostic 
value of CTCs using the CellSearch System in patients 
with metastatic breast cancer was independent of pheno-
type and has superior value compared to standard and 
functional imaging with [18F]ﬂ  uorodeoxyglucose  posi-
tron emission tomography [19]. Moreover, recent data 
indicate that CTCs represent a heterogeneous popu  lation 
that includes cells that have lost epithelial markers and 
have undergone EMT. Indeed, CTCs are characterized by 
higher expression of HER2 and loss of estrogen receptor 
expression compared to cancer cells isolated from the 
primary or metastatic tumors. Furthermore, additional 
phenotypic features suggest correlation with tumor-
initiating cancer cells (for example, expression of 
Notch-1). Dr Cristofanilli speculated that a more global 
assessment of the microscopic disease may facilitate its 
use for monitoring and therapeutic targeting.
Th  e challenges of using CTCs in clinical trials were 
addressed by Michalis Ignatiadis (Jules Bordet Institute, 
Brussels, Belgium). He pointed out that CTCs are already 
an integral part of ongoing studies such as the ALTTO 
trial in the adjuvant setting and the randomized SWOG 
0500 study in metastatic disease, where the detection of 
CTCs at baseline and after the ﬁ  rst cycle of front-line 
chemotherapy will guide treatment strategies. He also 
presented the outline of the ‘TREAT CTC’ trial, which 
will examine the role of trastuzumab as secondary 
adjuvant therapy in women with HER2-negative early 
breast cancer who have detectable HER2-positive CTCs.
Dave Hoon (John Wayne Cancer Institute, Santa 
Monica, CA, USA) reported on data from two inter-
national randomized phase III studies involving a 
melanoma vaccine in surgically resected stage III or IV 
melanoma patients where CTCs were detected at 
diﬀ   erent time-points using optimized multimarker 
quantitative real-time RT-PCR. In both studies pre-
treatment detection of CTCs could provide signiﬁ  cant 
prediction of DFS and OS in a multivariate analysis. 
Th   ese results indicate that CTC detection could be used 
Lianidou et al. Breast Cancer Research 2010, 12:307 
http://breast-cancer-research.com/content/12/4/307
Page 3 of 5for stratiﬁ  cation of melanoma patients for better disease 
management.
Data from CTC studies in castration-resistant prostate 
cancer patients treated with abiraterone acetate, a highly 
speciﬁ  c CYP17 inhibitor, were presented by Gert Attard 
(Institute of Cancer Research, London, UK) [20]. A 
decline in CTC count of ≥30% during treatment with 
administration of abiraterone acetate was associated with 
a signiﬁ  cant improvement in OS. Dr Attard suggested 
that circulating, non-apoptotic, nucleated EpCAM+/CK+/
CD45- cells are malignant in origin and that CTCs could 
be used to molecularly characterize castration-resistant 
prostate cancer.
Novel technologies for the isolation, detection and 
characterization of CTCs
Jonathan Uhr (University of Texas, Dallas, Texas, USA) 
presented a new technology for CTC characterization, 
based on a combination of hyper-spectral microscopic 
imaging and a microchip instrument using an immune-
magnetic approach, to precisely quantify 17 diﬀ  erent 
tumor markers in individual breast cancer cells from 
either touch preps of the primary tumor or CTCs in 
patients with tumor progression.
Leon Terstappen (University of Twente, Enschede, Th  e 
Netherlands) presented improvements on the CellSearch 
System to detect more treatment targets on CTCs and 
stated that CTCs in blood of patients at primary diag-
nosis and after surgical intervention are quite diﬀ  erent 
from CTCs in the metastatic setting. Molecular charac-
teri  zation of CTCs by ﬂ  uorescence in situ hybridization 
has shown that most CTCs in hormone refractory 
prostate cancer are aneuploid, showing an extensive 
hetero  geneity in the copy number of each of the 
chromosomes [21].
Richard Cote (Miller School of Medicine, Miami, FL, 
USA) presented a novel membrane microﬁ  lter device to 
isolate CTCs from blood with recovery rates of spiked 
tumor cells greater than 90% by exploiting size diﬀ  erences 
between tumor and normal blood cells. His group 
developed a quadruplex multimarker immunoﬂ  uorescent 
assay that can be performed and evaluated directly on the 
microﬁ  lter device simultaneously, assessing CD44, CD24, 
ALD1 and cytokeratin using quantum dots as labels. Th  e 
ability to eﬃ   ciently capture CTCs on a small ﬁ  lter area 
and then analyze these cells on the same platform can 
substantially facilitate further detailed analysis of early 
and late events in metastasis.
According to Catherine Alix-Panabières (Hôpital Saint-
Eloi - CHRU, Montpellier, France), who described the 
‘EPISPOT’ assay, many patients harbor viable DTCs in 
bone marrow, even in cases with apparently localized 
tumors. In rare cases of breast cancer, CTCs can release 
HER2 as a potential mechanism to escape HER2-directed 
therapy [22], while in prostate cancer, a signiﬁ  cant 
fraction of CTCs secreted ﬁ  broblast growth factor-2, a 
known stem cell growth factor.
Evi Lianidou (University of Athens, Greece) presented 
a novel real-time multiplex PCR assay for the simul-
taneous quantiﬁ  cation of CK-19, MAGE-A3, HER2 and 
PBGD in CTCs of breast cancer patients, and a multi-
plexed PCR-coupled liquid bead array for the simul-
taneous detection of CK-19, HER2, Mammaglobin, 
MAGE-A3, TWIST-1 and PBGD as a control, in a very 
limited amount of sample, thus saving sample volume 
and reducing the total cost and time of analysis.
Morphologic and molecular characterization of CTCs 
at the single cell level were discussed in the context of 
individual patient management by Peter Kuhn (Th  e 
Scripps Research Institute, La Jolla, CA, USA) and CTC 
analysis results from a small series case study in non-
small cell lung cancer patients were compared with 
clinical progression.
Carl Wittwer (University of Utah, Salt Lake City, UT, 
USA) highlighted the importance of real-time PCR in the 
quantitative assessment of speciﬁ  c transcripts in minimal 
residual disease monitoring and described recent 
advances in high resolution melting analysis for variant 
scanning and genotyping.
Conclusions and future perspectives
In his key note lecture Klaus Pantel (University of 
Hamburg, Germany), who is the founder of this inter-
national meeting series, pointed out that detection of 
CTCs/DTCs may contribute to early cancer detection 
and provide independent prognostic information. More-
over,  monitoring of CTCs/DTCs may become a bio-
marker for prediction of therapeutic eﬃ   cacy in cancer 
patients, and CTC/DTC analyses may improve stratiﬁ  -
cation of patients in need of (neo)adjuvant therapies. In 
this context, characterization of CTCs/DTCs opens a 
new avenue for identiﬁ  cation of therapeutic targets and 
understanding resistance to therapies. Last but not least, 
research on CTCs/DTCs will contribute to a better 
understanding of the biology of metastatic development 
in cancer patients. Th  e functional relevance of these 
ﬁ   ndings can then be cross-validated in appropriate 
animal models. If the few CTCs/DTCs found in human 
blood or bone marrow samples grow in mice, it would be 
almost a proof of their stem cell nature.
Th   e upcoming 8th International Symposium on 
Minimal Residual Cancer will be held in Osaka, Japan 
from 21 to 23 September 2011, organized by Professor 
Masaki Mori (Osaka University).
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